CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
52 hedge funds and large institutions have $145M invested in CERo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 5 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
13% more funds holding
Funds holding: 46 → 52 (+6)
2.69% more ownership
Funds ownership: 75.72% → 78.41% (+2.7%)
4% more capital invested
Capital invested by funds: $139M → $145M (+$5.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
+$4.63M |
| 2 |
SCM
Saba Capital Management
New York
|
+$3.99M |
| 3 |
FTCM
First Trust Capital Management
Chicago,
Illinois
|
+$3.52M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.74M |
| 5 |
HSBC Holdings
London,
United Kingdom
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$12.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.5M |
| 3 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$3.81M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$2.6M |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$152K |
CERO Hedge Fund Activity: Q2 2022 in Review
52 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q2 2022, worth a combined $145M — up 3.8% from $139M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new CERO positions and 5 closed out — a net gain of 6 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Westchester Capital Management (New York), opening a new position worth an estimated $4.63M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $12.3M sold.
- 52 institutional investors held CERo Therapeutics (CERO) as of Q2 2022, up from 46 in Q1 2022.
- Funds reported $145M of CERo Therapeutics stock for Q2 2022, up 3.8% quarter-over-quarter.
- 11 funds opened new CERo Therapeutics positions in Q2 2022 and 5 closed out, a net change of +6 holders.
- The largest CERo Therapeutics buyer in Q2 2022 was Westchester Capital Management (New York), an estimated $4.63M added.
- The largest CERo Therapeutics seller in Q2 2022 was Beryl Capital Management, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2022.